JP Morgan Maintains Neutral on Dyne Therapeutics, Lowers Price Target to $16
Benzinga Newsdesk 9 months ago
NewsPrice TargetAnalyst Ratings
JP Morgan analyst Tessa Romero maintains Dyne Therapeutics (NASDAQ:DYN) with a Neutral and lowers the price target from $17 to $16.
JP Morgan analyst Tessa Romero maintains Dyne Therapeutics (NASDAQ:DYN) with a Neutral and lowers the price target from $17 to $16.